+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Drug Addiction. Research Frontiers and Treatment Advances, Volume 1120. Annals of the New York Academy of Sciences

  • ID: 2178907
  • Book
  • December 2008
  • Region: United States
  • 400 Pages
  • John Wiley and Sons Ltd
1 of 3
This volume brings together basic and clinical science to provide in–depth understanding and current knowledge concerning new conceptual insights into the CNS acting drugs and drugs of abuse and treatment of drug addiction.

Methamphetamine, MDMA, PMA and different solvents are the most widely abused drugs in the Europe, United States, Central America, South America and Asian Countries and their use has dramatically increased over the last two decades. These drugs of abuse are known to cause neurotoxicity in several species including not only rodents, dogs and nonhuman primates, but also humans. However, precise neurochemical mechanisms underlying this drug–induced neurotoxicity remain unclear.

This volume addresses the following:
1) Role of Genomics, Proteomics and Metabonomics in Drug–induced Neurotoxicity
2) Drugs of Abuse and Medication Development
3) Molecular Biology and Free Radicals in Drugs of Abuse–induced neurotoxicity
4) Substituted Amphetamines–induced Neurochemical Changes and Relationship to Neurotoxicity
5) Drug of Abuse and Imaging Brain Structure and Function
6) GHB/Volatile Solvent/Inhalant Neurotoxicity

NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit [external URL]

ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order ([external URL] Members of the New York Academy of Science receive full–text access to the Annals online and discounts on print volumes. Please visit [external URL] for more information about becoming a member.
Note: Product cover images may vary from those shown
2 of 3
Part I: Gene Regulation and Drug Abuse:.

1. c–Fos Is an Intracellular Regulator of Cocaine–induced Long–term Changes: Ming Xu.

2. The Expression of NMDA Receptor Subunit mRNA in Human Chronic Alcoholics: Influence of Cirrhosis and Genotype: Justin P. Ridge, Ada M.–C. Ho, David J.Innes, and Peter R. Dodd.

3. Dopamine Receptor d4 Gene 521c/t polymorphism Is Associated with Opioid Dependence through Cold–Pain Responses: Ada M.–C. Ho, Nelson L.–S.Tang, Ben K.–L. Cheung, and Alfreda. Stadlin.

4. Injection of the Neuropeptide CNP into Dopaminergic Rat Brain Areas Decreases Alcohol Intake: Pascal Romieu, Serge Gobaille, Dominique Aunis, and Jean Zwiller.

5. Transcriptional Correlates of Human Substance Use: Elin Lehrmann and William J. Freed.

6. Association Study between Casein Kinase 1 Epsilon Gene and Methamphetamine Dependence: T. Kotaka, H. Ujike, Y. Morita, M. Kishimoto, Y. Okahisa, T. Inada, M. Harano, T. Komiyama, T. Hori, M. Yamada, Y. Sekine, N. Iwata, M. Iyo, I. Sora, N. Ozaki, and S. Kuroda.

7. Short Allele of 5–HTTLPR As a Risk Factor for the Development of Psychosis in Japanese Methamphetamine Abusers: Norikazu Ezaki, Kazuhiko Nakamura, Yoshimoto Sekine, Ismail Thanseem, Ayyappan Anitha, Yasuhide Iwata, Masayoshi Kawai, Kiyokazu Takebayashi, Katsuaki Suzuki, Nori Takei, Masaomi Iyo, Toshiya Inada, Nakao Iwata, Mutsuo Harano, Tokutaro Komiyama, Mitsuhiko Yamada, Ichiro Sora, Hiroshi Ujike, and Norio Mori.

8. Association Study of the Calcineurin A Gamma Subunit Gene (PPP3CC) and Methamphetamine Use Disorder in the Japanese Population. A Collaborative Study by Japanese Genetics Iinitiative for Drug Abuse: Y. Kinoshita, M. Ikeda, H. Ujike, T. Kitajima, Y. Yamanouchi, B. Aleksic, T. Kishi, K. Kawashima, T. Ohkouchi, N. Ozaki, T. Inada, M. Harano, T. Komiyama, T. Hori, M. Yamada, Y. Sekine, M, Iyo, I. Sora, and N. Iwata.

9. Glutamate Cysteine Ligase Modifier (GCLM) Subunit Gene Not Associated with Methamphetamine Use Disorder and Schizophrenia in the Japanese Population: Taro Kishi, Masashi Ikeda, Tsuyoshi Kitajima, Yoshio Yamanouchi, Yoko Kinoshita, Kunihiro Kawashima, Toshiya Inada, Mutsuo Harano, Tokutaro Komiyama, Toru Hori, Mitsuhiko Yamada, Masaomi Iyo, Ichiro Sora, Yoshimoto Sekine, Norio Ozaki, Hiroshi Ujike, and Nakao Iwata.

10. No Association between Alpha4 and Beta2 Subunits of Neuronal Nicotinic Acetylcholine Receptor Genes and Methamphetamine Use Disorder in the Japanese Population: Taro Kishi, Masashi Ikeda, Tsuyoshi Kitajima, Yoshio Yamanouchi, Yoko Kinoshita, Kunihiro Kawashima, Toshiya Inada, Mutsuo Harano, Tokutaro Komiyama, Toru Hori, Mitsuhiko Yamada, Masaomi Iyo, Ichiro Sora, Yoshimoto Sekine, Norio Ozaki, Hiroshi Ujike, and Nakao Iwata.

11. No Association between Prostate Apoptosis Response 4 Gene (PAWR) and Methamphetamine Use Disorder in the Japanese Population: Taro Kishi, Masashi Ikeda, Tsuyoshi Kitajima, Yoshio Yamanouchi, Yoko Kinoshita, Kunihiro Kawashima, Toshiya Inada, Mutsuo Harano, Tokutaro Komiyama, Toru Hori, Mitsuhiko Yamada, Masaomi Iyo, Ichiro Sora, Yoshimoto Sekine, Norio Ozaki, Hiroshi Ujike, Nakao Iwata.

12. Transient Enhanced Expression of cdk5 Activator p25 after Acute and Chronic d–Amphetamine Administration: Estela Cecilia Mlewski, Favio Ariel Krapacher, Soledad Ferreras, and Gabriela Paglini.

13. Methamphetamine–induced Early Increase of IL–6 and TNF– mRNA Expression in the Mice Brain: Joana Gonçalves, Tânia Martins, Raquel Ferreira, Nuno Milhazes, Fernanda Borges, Carlos Fontes Ribeiro, João O. Malva, Tice R. Macedo, and Ana P. Silva.

Part II: Substituted Amphetamine Neurotoxicity:.

14. Differential Response of Neurotensin to Methamphetamine Self–administration: Role of Contingency: Paul S. Frankel, Amanda J. Hoonakker, and Glen R. Hanson.

15. Dopamine Disposition in the Presynaptic Process Regulates the Severity of Methamphetamine–Induced Neurotoxicity: Donald M. Kuhn, Dina M. Francescutti–Verbeem, and David M. Thomas.

16. The Relative Importance of Dose, Hyperthermia, Seizures and the Blood Brain Barrier in the Brain Region Specific Neurodegenerative Profiles Induced by Amphetamine: John F. Bowyer, Monzy Thomas, Larry C. Schmued, and Syed Ali.

17. Sex Differences in Dopamine– and Vesicular Monoamine–transporter Functions: Implications for Methamphetamine Use and Neurotoxicity: D. E. Dluzen and J. L. McDermott.

18. Development and Characterization of a Novel Animal Model of Intermittent MDMA ("Ecstasy") Exposure During Adolescence: Jerrold S. Meyer, Brian J. Piper, and Valerie E. Vancollie.

19. Connection Between the Striatal Neurokinin–1 Receptor and Nitric Oxide Formation During Methamphetamine Exposure: Jing Wang, Wenjing Xu, Syed F. Ali, and Jesus A. Angulo.

20. The Agonist of M(1)–Muscarinic Acetylcholine Receptor Agonist Prevents Neurotoxicity Induced by Amphetamine Via Nitric Oxide Pathway: Valentina Bashkatova, Ariane Hornick, Anatoly Vanin, and Helmut Prast.

21. Pathways of Methamphetamine Toxicity: Effects of Autophagy and SOD Alteration in the Spinal Cord: Michela Ferrucci, Livia Pasquali, Antonio Paparelli, Stefano Ruggieri, and Francesco Fornai.

22. Analysis of Single, Purified Inclusions as a Novel Approach to Understand Methamphetamine Neurotoxicity: Paola Lenzi, Federica Fulceri, Gloria Lazzeri, Alessandro Casini, Stefano Ruggieri, Antonio Paparelli, and Francesco Fornai.

23. Role of Autophagy during Methamphetamine Neurotoxicity: Livia Pasquali, Gloria Lazzeri, Ciro Isidoro, Stefano Ruggieri, Antonio Paparelli, and Francesco Fornai.

24. Chronic Low Dose Oxidative Stress Induces Caspase–3 Dependent PKC Proteolytic Activation and Apoptosis in a Cell Culture Model of Dopaminergic Neurodegeneration: Martha Carvour, Chunjuan Song, Siddharth Kaul, Vellareddy Anantharam, Anumantha Kanthasamy, and Arthi Kanthasamy.

25. A Role for mGluR5 Receptors in Intravenous Methamphetamine Self–administration: Megan P.H. Osborne and M. Foster Olive.

26. Acute Increase of the Glutamate–Glutamine Cycling in Discrete Brain Areas upon A Single Amphetamine Administration: Frederico C. Pereira, Marta R. Rolo, Elsa Marques, Vera M. Mendes, Carlos F. Ribeiro, Syed F. Ali, Teresa Morgadinho, and Tice R. Macedo.

27. Influence of Chronic Exercise on the Amphetamine–induced Dopamine Release and Neurodegeneration in the Striatum of the Rat: Elsa Marques, Filipa Vasconcelos, Marta Rolo, Frederico C. Pereira, Ana P. Silva, Tice R. Macedo, and Carlos F. Ribeiro.

28. Methamphetamine Changes NMDA and AMPA Glutamate Receptor Subunit Levels in the Rat Striatum and Frontal Cortex: Patricia F. Simões, Ana P. Silva, Frederico C. Pereira, Elsa Marques, Nuno Milhazes,Fernanda Borges,Carlos F. Ribeiro, and Tice R. Macedo.

29. Acute Administration of 3,4–Methylenedioxymethamphetamine (MDMA, "Ecstasy") Induces Profound Hyperthermia, Blood–brain Barrier Disruption, Brain Edema Formation and Cell Injury: Hari Shanker Sharma and Syed F. Ali.

30. Effect of Acetaldehyde on Behavioral and Neurochemical Changes Induced by MK–801 in Rats: Mónica Padilla–de la Torre, Javier Franco–Pérez, Abel Santamaría, Sonia Galvan, Edith González, and Carlos Paz.

Part III: Therapeutic Approaches to Drug Addiction:.

31. Serotonin (5–HT) Transporter Ligands Affect Plasma 5–HT in Rats: Implications for Medication Development: Richard B. Rothman, Dorota Zolkowska, and Michael H. Baumann.

32. Methylphenidate–induced Alteration in Synaptic Vesicle Trafficking and Activity: Functional Consequences and Therapeutic Implications: Trent J. Volz, Sarah J. Farnsworth, Glen R. Hanson, and Annette E. Fleckenstein.

33. Neuroimaging in Human MDMA (Ecstasy) Users: A Cortical Model: Ronald L Cowan, Deanne M. Roberts, and James M. Joersc.

34. Addiction and Cognitive Functions: Saturnino Spiga, Alessandra Lintas, and Marco Diana.

35. Crucial Role of Acetaldehyde in Alcohol Activation of the Mesolimbic Dopamine System: Marco Diana, Alessandra Tiziana Peana, Donatella Sirca, Alessandra Lintas, Miriam Melis, and Paolo Enrico.

Part IV: METH and MPTP: Similarities and Differences:.

36. Defining Neuroinflammation : Lessons from MPTP– and Methamphetamine–Induced Neurotoxicity: James P. O Callaghan, Krishnan Sriram, and Diane B. Miller.

37. Extranigral Neurodegeneration in Parkinson s Disease: A Role for Calpain in Neurodegeneration: Supriti Samantaray, Jonathan T. Butler, Swapan K. Ray, and Naren L. Banik.

38. Methamphetamine Fails to Alter the Noradrenergic Integrity of the Heart: A Comparison with the Parkinsonism–inducing Neurotoxin MPTP: Riccardo Ruffoli, Paola Soldani, Livia Pasquali, Stefano Ruggieri, Antonio Paparelli, and Francesco Fornai.

39. MPTP–But Not Methamphetamine–induced Parkinsonism Extends to Catecholamine Neurons in the Gut: Gianfranco Natale, Olga Kastsiuchenka, Licia Pasquali, Stefano Ruggieri, Antonio Paparelli, and Francesco Fornai.

Part V: Psychostimulants/Cocaine:.

40. Role of the NMDA Receptor and Nitric Oxide in Memory Reconsolidation of Cocaine–Induced Conditioned Place Preference in Mice: Yossef Itzhak.

41. Exploratory Behavior on Rats Postnatally Exposed to Cocaine and Housed in Enriched Environment: Ana Magalhães, Pedro Melo, Cecília Juliana Alves, Maria Amélia Tavares, Liliana de Sousa, and Teresa Summavielle.

42. Hormonal, Neurochemical and Behavioral Response to a Forced Swim Test in Adolescent Rats throughout Cocaine Withdrawal: Cecília Juliana Alves, Ana Magalhães, Teresa Summavielle, Pedro Melo, Liliana De Sousa, Maria Amélia Tavares, and Pedro R.R. Monteiro.

Part VI: GHB/GBL/1,4–BD and Dexmethorphan:.

43. Characterization and Pharmacology of GHB Receptor. By Maharaj K. Ticku and Ashok K. Mehta –hydroxybutyric Acid–induced Cognitive Deficits in Female Adolescent Rat: Ratna Sircar, Ashim Basak, and Debashish Sircar.

44. Toluene and TCE Decrease Binding to Mu Opioid Receptors, but not to Benzodiazepine and NMDA Receptors in Mice Brain: N. Páez–Martínez, E. Ambrosio, C. García–Lecumberri, L. Rocha, G. L. Montoya, and S. L. Cruz.

45. Dextromethorphan: An Emerging Drug of Abuse: Joseph A. Banken and Howell Foster.

Part VII: Nicotine, Marijuana, and Alcohol:.

46. An Endocannabinoid Hypothesis of Drug Reward and Drug Addiction: Emmanuel S. Onaivi.

47. Screening for Marihuana and Cocaine Abuse in a College Population of Universidad Autonoma del Estado de Morelos in Mexico+, by Immunoanalysis and Gas Chromatographic Method: An Exploratory Study: Sara Garcia–Jimenez, Karina Heredia–Lezama, Fernando Bilbao–Marcos, Griselda Fuentes–Lara, Antonio Monroy–Noyola, and Myrna Deciga–Campos.

48. Behavioral Effects of CB2 Cannabinoid Receptor Activation and Its Influence on Food and Alcohol Consumption: E. S. Onaivi, O. Carpio, H. Ishiguro, N. Schanz, G. R. Uhl, and R. Benno.

49. Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors are Involved in the Effects of Drugs of Abuse and in Depression: Emmanuel S. Onaivi, Hiroki Ishiguro, Jian–Ping Gong, Sejal Patel, Paul A. Meozzi, Lester Myers, Alex Perchuk, Zoila Mora,Patricia A. Tagliaferro, Eileen Gardner, Alicia Brusco, B. Emmanuel Akinshola, Qing–Rong Liu, Sanika S. Chirwa, Bruce Hope, Javier Lujilde, Toshiya Inada, Shinya Iwasaki, David Macharia, Lindsey Teasenfitz, Tadao Arinami, and George R. Uhl.

50. Ultrastructural Localization of Neuronal Brain CB2 Cannabinoid Receptors: A. Brusco, P. Tagliaferro, T. Saez, and E. S. Onaivi.

51. Psychosocial Withdrawal Characteristics of Nicotine Compared with Alcohol and Caffeine: Hisatsugu Miyata, Naoyuki Hironaka, Kohji Takada, Katsumasa Miyasato, Koichi Nakamura, and Tomoji Yanagita.

52. Prenatal Nicotine and or Cocaine Differentially Alters Nicotine–induced Sensitization in Aging Offspring: Sonya K. Sobrian, Matthew Johnston, Jewel Wright, Daniela Kuhn, and Kamal Ameis.

53. Prenatal Ethanol Exposure Reduces the Expression of the Transcriptional Factor Pax6 in the Developing Rat Brain: Maria Paula Aronne,Sergio Gustavo Evrard, Sebastian Mirochnic, and Alicia Brusco

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Syed F. Ali
Michael J. Kuhar
Note: Product cover images may vary from those shown